Y Zhou1, M J Barnett, J K Rivers. 1. Department of Medicine, Vancouver General Hospital and University of British Columbia.
Abstract
OBJECTIVE: To determine the value of skin biopsies in the management of suspected graft-vs-host disease (GVHD) within 30 days of allogeneic bone marrow transplantation (BMT). DESIGN: Retrospective study based on review of a BMT database. SETTING: Leukemia/BMT ward of a tertiary care, university teaching hospital. PATIENTS: One hundred and eighty-seven consecutive patients who received allogeneic BMT between January 1, 1994, and June 30, 1997, at Vancouver General Hospital, Vancouver, British Columbia. MAIN OUTCOME MEASURES: (1) Skin biopsy frequency for patients with rashes suggestive of acute GVHD; (2) clinical significance of skin biopsy in the management of patients with suspected acute GVHD after BMT; (3) relationship between severity of clinical GVHD and the likelihood to receive GVHD therapy; and (4) relationship between biopsy status or biopsy result and outcome of BMT (acute and chronic GVHD, transplant-related mortality, and overall and event-free survival). RESULTS: During the early post-BMT period (<30 days after BMT), 88 patients had rashes suggestive of acute GVHD; of these, 51 (58%) underwent skin biopsy to confirm the diagnosis. Skin biopsies were performed more often for higher clinical stages of cutaneous GVHD. There was no significant difference between the patients with positive biopsy findings and those with negative findings, either in the clinical severity of acute GVHD or in likelihood to receive treatment for GVHD. Most (85%) of the patients who underwent biopsies and received GVHD therapy had treatment initiated before skin biopsies were performed or before the results were available. The higher the clinical grade of overall acute GVHD, the more likely it was that the patients were treated for GVHD (P<.001). The outcome of BMT was not influenced by the skin biopsy status or biopsy result. CONCLUSIONS: The biopsy findings correlated poorly with the clinical severity of skin rash suggestive of acute GVHD soon after BMT. The decision to treat suspected acute GVHD depended not on skin biopsy findings but rather on clinical severity of acute GVHD. In this regard, skin biopsy has a limited role in the management of patients early after allogeneic BMT.
OBJECTIVE: To determine the value of skin biopsies in the management of suspected graft-vs-host disease (GVHD) within 30 days of allogeneic bone marrow transplantation (BMT). DESIGN: Retrospective study based on review of a BMT database. SETTING:Leukemia/BMT ward of a tertiary care, university teaching hospital. PATIENTS: One hundred and eighty-seven consecutive patients who received allogeneic BMT between January 1, 1994, and June 30, 1997, at Vancouver General Hospital, Vancouver, British Columbia. MAIN OUTCOME MEASURES: (1) Skin biopsy frequency for patients with rashes suggestive of acute GVHD; (2) clinical significance of skin biopsy in the management of patients with suspected acute GVHD after BMT; (3) relationship between severity of clinical GVHD and the likelihood to receive GVHD therapy; and (4) relationship between biopsy status or biopsy result and outcome of BMT (acute and chronic GVHD, transplant-related mortality, and overall and event-free survival). RESULTS: During the early post-BMT period (<30 days after BMT), 88 patients had rashes suggestive of acute GVHD; of these, 51 (58%) underwent skin biopsy to confirm the diagnosis. Skin biopsies were performed more often for higher clinical stages of cutaneous GVHD. There was no significant difference between the patients with positive biopsy findings and those with negative findings, either in the clinical severity of acute GVHD or in likelihood to receive treatment for GVHD. Most (85%) of the patients who underwent biopsies and received GVHD therapy had treatment initiated before skin biopsies were performed or before the results were available. The higher the clinical grade of overall acute GVHD, the more likely it was that the patients were treated for GVHD (P<.001). The outcome of BMT was not influenced by the skin biopsy status or biopsy result. CONCLUSIONS: The biopsy findings correlated poorly with the clinical severity of skin rash suggestive of acute GVHD soon after BMT. The decision to treat suspected acute GVHD depended not on skin biopsy findings but rather on clinical severity of acute GVHD. In this regard, skin biopsy has a limited role in the management of patients early after allogeneic BMT.
Authors: I Saknite; M Gill; C Alessi-Fox; M Byrne; M Jagasia; S Gonzalez; M Ardigo; E R Tkaczyk Journal: Br J Dermatol Date: 2019-07-15 Impact factor: 9.302
Authors: Thomas Weber; Andreas Schmidberger; Kinga Ligeti; Marcus Bauer; Andreas Rosenwald; Lutz P Müller Journal: Acta Haematol Date: 2020-09-09 Impact factor: 2.195
Authors: Alyssa Fischer; Ann A Jakubowski; Mario E Lacouture; Travis J Hollmann; Aaron M Drucker; Molly Maloy; Susan Prockop; Christiane Querfeld; Klaus J Busam; Melissa P Pulitzer Journal: Am J Dermatopathol Date: 2015-07 Impact factor: 1.533
Authors: Skylar Klager; Mario E Lacouture; Margaret Hannum; Sean M Devlin; Molly Maloy; Melissa Pulitzer; Ann A Jakubowski; Alina Markova Journal: Biol Blood Marrow Transplant Date: 2019-07-12 Impact factor: 5.742
Authors: Andreas Kreft; Anja Mottok; Ildiko Mesteri; Diana M Cardona; Anne Janin; Anja A Kühl; Mindaugas Andrulis; Andrea Brunner; Howard M Shulman; Giovanni Negri; Alexandar Tzankov; Elisabeth Huber Journal: Virchows Arch Date: 2015-07-12 Impact factor: 4.064
Authors: I Saknite; M Gill; C Alessi-Fox; J P Zwerner; J S Lehman; M M Shinohara; R A Novoa; H Chen; M Byrne; S Gonzalez; M Ardigo; E R Tkaczyk Journal: J Eur Acad Dermatol Venereol Date: 2022-03-22 Impact factor: 9.228
Authors: Rachel E Reingold; Jilliana Monnier; Marco Ardigò; Joseph R Stoll; Maria C Pena; Japbani K Nanda; Stephen W Dusza; Josel D Ruiz; Lisa Flynn; Antara Afrin; Elizabeth G Klein; Susan E Prockop; Melissa P Pulitzer; Doris M Ponce; Alina Markova; Manu Jain Journal: Transplant Cell Ther Date: 2021-09-24